These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 738344)
1. Adriamycin in ovarian cancer patients resistant to cyclophosphamide. Bolis G; D'Incalci M; Gramellini F; Mangioni C Eur J Cancer (1965); 1978 Dec; 14(12):1401-2. PubMed ID: 738344 [No Abstract] [Full Text] [Related]
2. Hexamethylmelamine in ovarian cancer resistant to cyclophosphamide and adriamycin. Bolis G; D'Incalci M; Belloni C; Mangioni C Cancer Treat Rep; 1979 Aug; 63(8):1375-7. PubMed ID: 113096 [TBL] [Abstract][Full Text] [Related]
3. Adriamycin, BCNU, and cyclophosphamide in drug-resistant adenocarcinoma of the ovary. Presant CA; Bartolucci A Med Pediatr Oncol; 1983; 11(3):151-3. PubMed ID: 6682929 [TBL] [Abstract][Full Text] [Related]
4. Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. A randomized clinical study. Bolis G; Bortolozzi G; Carinelli G; D'Incalci M; Gramellini F; Morasca L; Mangioni C Cancer Chemother Pharmacol; 1980; 4(2):129-32. PubMed ID: 7389058 [TBL] [Abstract][Full Text] [Related]
5. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Rogan AM; Hamilton TC; Young RC; Klecker RW; Ozols RF Science; 1984 Jun; 224(4652):994-6. PubMed ID: 6372095 [TBL] [Abstract][Full Text] [Related]
9. [Controlled prospective study of chemotherapy in advanced ovarian cancer--cyclophosphamide monochemotherapy versus polychemotherapy with adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate]. Chylak V; Kolarić K; Krusić J Lijec Vjesn; 1987 Jun; 109(6):230-4. PubMed ID: 3309515 [No Abstract] [Full Text] [Related]
10. Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Griffiths CT; Fuller AF Surg Clin North Am; 1978 Feb; 58(1):131-42. PubMed ID: 417410 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of intraperitoneal doxorubicin in combination with systemic cyclophosphamide and cis-platinum in the treatment of stage III ovarian cancer. Malviya VK; Deppe G; Boike G; Young J Gynecol Oncol; 1990 Feb; 36(2):185-8. PubMed ID: 2298407 [TBL] [Abstract][Full Text] [Related]
12. Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial. Sessa C; Bolis G; Colombo N; D'Incalci M; Mermillod B; Valente I; Mangioni C Cancer Chemother Pharmacol; 1985; 14(3):222-8. PubMed ID: 3922639 [TBL] [Abstract][Full Text] [Related]
14. Chemoimmunotherapy for advanced ovarian carcinoma with adriamycin-cyclophosphamide +/- BCG: early report of a Southwest Oncology Group study. Alberts DS; Salmon SE; Moon TE Recent Results Cancer Res; 1978; 68():160-5. PubMed ID: 752854 [No Abstract] [Full Text] [Related]
15. Cisplatin, adriamycin and cyclophosphamide (PACe) combination chemotherapy in patients with ovarian carcinoma resistant to chlorambucil. Mead GM; Williams CJ; Whitehouse JM Cancer Chemother Pharmacol; 1985; 15(2):179-80. PubMed ID: 3839443 [TBL] [Abstract][Full Text] [Related]
16. Combined cyclophosphamide, adriamycin and cis-platinum in advanced ovarian cancer resistant to chlorambucil and cis-platinum. Mann GJ; Malden LT; Solomon HJ; Tattersall MH Gynecol Oncol; 1985 Jun; 21(2):215-9. PubMed ID: 3886497 [TBL] [Abstract][Full Text] [Related]
17. Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone. Frederiksen PL; Joergensen ST; Roesdahl K; Thomsen J; Mouridsen HT Cancer Treat Rep; 1978 Mar; 62(3):449-50. PubMed ID: 348314 [No Abstract] [Full Text] [Related]
18. Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer. Fleming GF; Waggoner SE; Rotmensch J; Skoog LA; Langhauser C Gynecol Oncol; 1997 Apr; 65(1):42-5. PubMed ID: 9103389 [TBL] [Abstract][Full Text] [Related]
19. [Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients]. Salzer H; Gitsch E; Dittrich C; Sevelda P; Karrer K; Schemper M; Stempel-Smekal G; Langer M; Wagner G; Rainer H Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):761-8. PubMed ID: 3908214 [TBL] [Abstract][Full Text] [Related]
20. [Analysis of the effectiveness and adverse effects of the drug combinations CAP and CEP in the therapy of patients in the advanced stages of ovarian cancer]. Hernádi Z; Juhász B; Póka R; Mahunka I; Lampé L Orv Hetil; 1987 Nov; 128(47):2457-61. PubMed ID: 3320851 [No Abstract] [Full Text] [Related] [Next] [New Search]